|
Name |
gibberellin A24(2-)
|
| Molecular Formula | C20H24O5-2 | |
| IUPAC Name* |
(1R,2S,3S,4R,8R,9R,12R)-8-formyl-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylate
|
|
| SMILES |
C[C@]1(CCC[C@@]2([C@@H]1[C@@H]([C@]34[C@H]2CC[C@H](C3)C(=C)C4)C(=O)[O-])C=O)C(=O)[O-]
|
|
| InChI |
InChI=1S/C20H26O5/c1-11-8-20-9-12(11)4-5-13(20)19(10-21)7-3-6-18(2,17(24)25)15(19)14(20)16(22)23/h10,12-15H,1,3-9H2,2H3,(H,22,23)(H,24,25)/p-2/t12-,13+,14-,15-,18-,19-,20+/m1/s1
|
|
| InChIKey |
QQRSSHFHXYSOMF-CXXOJBQZSA-L
|
|
| Synonyms |
gibberellin A24(2-); GA24; CHEBI:143957; (1R,2S,3S,4R,8R,9R,12R)-8-formyl-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylate
|
|
| CAS | NA | |
| PubChem CID | 25246232 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 344.4 | ALogp: | 3.6 |
| HBD: | 0 | HBA: | 5 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 97.3 | Aromatic Rings: | 4 |
| Heavy Atoms: | 25 | QED Weighted: | 0.559 |
| Caco-2 Permeability: | -5.861 | MDCK Permeability: | 0.00001410 |
| Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
| Human Intestinal Absorption (HIA): | 0.018 | 20% Bioavailability (F20%): | 0.601 |
| 30% Bioavailability (F30%): | 0.036 |
| Blood-Brain-Barrier Penetration (BBB): | 0.836 | Plasma Protein Binding (PPB): | 66.32% |
| Volume Distribution (VD): | 0.255 | Fu: | 24.32% |
| CYP1A2-inhibitor: | 0.004 | CYP1A2-substrate: | 0.148 |
| CYP2C19-inhibitor: | 0.01 | CYP2C19-substrate: | 0.079 |
| CYP2C9-inhibitor: | 0.01 | CYP2C9-substrate: | 0.224 |
| CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.112 |
| CYP3A4-inhibitor: | 0.145 | CYP3A4-substrate: | 0.026 |
| Clearance (CL): | 0.788 | Half-life (T1/2): | 0.777 |
| hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.137 |
| Drug-inuced Liver Injury (DILI): | 0.783 | AMES Toxicity: | 0.01 |
| Rat Oral Acute Toxicity: | 0.195 | Maximum Recommended Daily Dose: | 0.184 |
| Skin Sensitization: | 0.757 | Carcinogencity: | 0.337 |
| Eye Corrosion: | 0.886 | Eye Irritation: | 0.952 |
| Respiratory Toxicity: | 0.885 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002556 | ![]() |
0.773 | D0I1LH | ![]() |
0.273 | ||
| ENC002555 | ![]() |
0.590 | D0X7HM | ![]() |
0.247 | ||
| ENC002558 | ![]() |
0.462 | D0X4RS | ![]() |
0.235 | ||
| ENC002554 | ![]() |
0.457 | D02CJX | ![]() |
0.233 | ||
| ENC000794 | ![]() |
0.426 | D0IX6I | ![]() |
0.230 | ||
| ENC002541 | ![]() |
0.381 | D0KR5B | ![]() |
0.230 | ||
| ENC001071 | ![]() |
0.364 | D0I2SD | ![]() |
0.225 | ||
| ENC003145 | ![]() |
0.363 | D0V2JK | ![]() |
0.224 | ||
| ENC002542 | ![]() |
0.360 | D0Y3ME | ![]() |
0.224 | ||
| ENC003143 | ![]() |
0.315 | D08TEJ | ![]() |
0.223 | ||